Evercore began coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Free Report) in a research note released on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $43.00 price target on the stock.
Other analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Lycia Therapeutics to a “hold” rating in a research note on Saturday, October 31st. Jefferies Financial Group assumed coverage on shares of Lycia Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 price target for the company. Five investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $54.00.
Read Our Latest Research Report on Lycia Therapeutics
Lycia Therapeutics Stock Performance
Insider Buying and Selling at Lycia Therapeutics
In related news, major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of Lycia Therapeutics stock in a transaction dated Monday, November 2nd. The stock was acquired at an average price of $26.95 per share, for a total transaction of $223,819.75. Following the transaction, the insider owned 6,858,542 shares of the company’s stock, valued at $184,837,706.90. This represents a 0.12% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have purchased 2,078,749 shares of company stock worth $38,526,342.
Lycia Therapeutics Company Profile
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
Further Reading
- Five stocks we like better than Lycia Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
